US4585764A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Gastric cytoprotection with 3,3'-thiobis[propanoic acid] in oral administration of aspirin
Assignee: STWB Inc
•
Filing: 1985-04-22
•
Granted: 1986-04-29
•
Expires: 2005-04-22
Abstract
Abstract The method of providing cytoprotection of the gastric mucosa in a mammal receiving aspirin (ASA) perorally which comprises orally administering either prior to or in combination with ASA a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid] (TBPA) or in combination with a pharmaceutically acceptable carrier. Also shown is a composition for providing cytoprotection of the gastric mucosa in a mammal receiving ASA perorally which comprises ASA in combination with a cytoprotectively effective amount of TBPA.
Inventors
- 👤 Denis M. Bailey
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 04:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/60; A61K31/185; A61K31/19
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
49 words
The method of providing cytoprotection of the gastric mucosa in a mammal receiving aspirin perorally which comprises orally administering either prior to or in combination with aspirin a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid], using at least about 1 part of 3,3'-thiobis[propanoic acid] per part by weight of aspirin.
Claim 2
Independent Claim
49 words
The method of providing cytoprotection of the gastric mucosa in a mammal receiving aspirin perorally which comprises orally administering either prior to or in combination with aspirin a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid], using at least about 1 part of 3,3'-thiobis[propanoic acid] per part by weight of aspirin.
Claim 3
Dependent Claim
21 words
The method according to claim 1 wherein the combination of aspirin and 3,3'-thiobis[propanoic acid] is administered in a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
17 words
The method according to claim 1 wherein aspirin and 3,3'-thiobis[propanoic acid] are administered in combination dosage form.
Claim 5
Dependent Claim
28 words
The method according to claim 1 wherein about 1 to about 3 parts by weight of 3,3'-thiobis[propanoic acid] per part of aspirin are administered in combination dosage form.
Claim 6
Dependent Claim
23 words
The method according to claim 1 wherein about equal parts by weight of 3,3'-thiobis[propanoic acid] and aspirin are administered in combination dosage form.
Claim 7
Dependent Claim
17 words
The method according to claim 1 wherein aspirin and 3,3'-thiobis[propanoic acid] are administered in separate dosage form.
Claim 8
Independent Claim
48 words
The method of preventing or inhibiting gastric lesions in a mammal receiving aspirin perorally which comprises orally administering either prior to or in combination with aspirin a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid], using at least about 1 part of 3,3'-thiobis[propanoic acid] per part by weight of aspirin.
Claim 9
Independent Claim
48 words
The method of preventing or inhibiting gastric lesions in a mammal receiving aspirin perorally which comprises orally administering either prior to or in combination with aspirin a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid], using at least about 1 part of 3,3'-thiobis[propanoic acid] per part by weight of aspirin.
Claim 10
Dependent Claim
21 words
The method according to claim 7 wherein the combination of aspirin and 3,3'-thiobis[propanoic acid] is administered in a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
17 words
The method according to claim 7 wherein aspirin and 3,3'-thiobis[propanoic acid] are administered in combination dosage form.
Claim 12
Dependent Claim
28 words
The method according to claim 7 wherein about 1 to about 3 parts by weight of 3,3'-thiobis[propanoic acid] per part of aspirin are administered in combination dosage form.
Claim 13
Dependent Claim
23 words
The method according to claim 7 wherein about equal parts by weight of 3,3'-thiobis[propanoic acid] and aspirin are administered in combination dosage form.
Claim 14
Dependent Claim
17 words
The method according to claim 7 wherein aspirin and 3,3'-thiobis[propanoic acid] are administered in separate dosage form.
Claim 15
Dependent Claim
43 words
A composition for providing cytoprotection of the gastric mucosa in a mammal receiving aspirin perorally which comprises aspirin in combination with a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid], using at least about 1 part of 3,3'-thiobis[propanoic acid] per part by weight of aspirin.
Claim 16
Dependent Claim
43 words
A composition for providing cytoprotection of the gastric mucosa in a mammal receiving aspirin perorally which comprises aspirin in combination with a cytoprotectively effective amount of 3,3'-thiobis[propanoic acid], using at least about 1 part of 3,3'-thiobis[propanoic acid] per part by weight of aspirin.
Claim 17
Dependent Claim
18 words
A composition according to claim 13 comprising aspirin and 3,3'-thiobis[propanoic acid] in combination with a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
22 words
A composition according to claim 13 in unit dosage form comprising a mixture of aspirin and 3,3'-thiobis[propanoic acid] in a gelatin capsule.
Claim 19
Dependent Claim
29 words
A composition according to claim 13 in unit dosage form comprising a mixture of aspirin and 3,3'-thiobis[propanoic acid] in combination with a pharmaceutically acceptable excipient in a gelatin capsule.
Claim 20
Dependent Claim
26 words
A composition according to claim 13 in unit dosage tablet form comprising a mixture of aspirin and 3,3'-thiobis[propanoic acid] in combination with a pharmaceutically acceptable excipient.
Claim 21
Dependent Claim
22 words
A composition according to claim 13 comprising about 1 to about 3 parts by weight of 3,3'-thiobis[propanoic acid] per part of aspirin.
Claim 22
Dependent Claim
17 words
A composition according to claim 13 comprising about equal parts by weight of 3,3'-thiobis[propanoic acid] and aspirin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-04-28 | 1989-10-28 | 1990-04-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-04-28 | 1993-10-28 | 1994-04-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-04-28 | 1997-10-28 | 1998-04-29 | $7700.00 | Window Closed / Lapsed |